Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

BACKGROUND: Lanreotide depot/autogel antitumor activity in intestinal/pancreatic neuroendocrine tumors (NETs) was demonstrated in the phase-3 CLARINET study (NCT00353496), based on significantly prolonged progression-free survival (PFS) versus placebo. METHODS: During CLARINET, patients with metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dromain, Clarisse, Pavel, Marianne E., Ruszniewski, Philippe, Langley, Alison, Massien, Christine, Baudin, Eric, Caplin, Martyn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332566/
https://www.ncbi.nlm.nih.gov/pubmed/30642293
http://dx.doi.org/10.1186/s12885-018-5257-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332566/
https://www.ncbi.nlm.nih.gov/pubmed/30642293
http://dx.doi.org/10.1186/s12885-018-5257-x

Ejemplares similares